参考文献/References:
[1] 国家卫生健康委办公厅.原发性肝癌诊疗指南(2022年版)[J].临床肝胆病杂志,2022,38:288-303.
[2]Zhong BY,Jin ZC,Chen JJ,et al.Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma[J].J Clin Transl Hepatol,2023,11:480-489.
[3]Gordan JD,Kennedy EB,Abou-Alfa GK,et al.Systemic therapy for advanced hepatocellular carcinoma:ASCO guideline[J].J Clin Oncol,2020,38:4317-4345.
[4]Qiu Z,Shen L,Chen S,et al.Efficacy of apatinib in transcatheter arterial chemoembolization(TACE)refractory intermediate and advanced-stage hepatocellular carcinoma:a propensity score matching analysis[J].Cancer Manag Res,2019,11:9321-9330.
[5]Yin L,Liu KC,Lv WF,et al.Comparing the effectiveness and safety of sorafenib plus TACE with apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma:a multicentre propensity score matching study[J].Cancer Imaging,2023,23:52.
[6]Zhang TQ,Geng ZJ,Zuo MX,et al.Camrelizumab(a PD-1 inhibitor)plus apatinib(an VEGFR-2 inhibitor)and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C(TRIPLET):a phase Ⅱ study[J].Signal Transduct Target Ther,2023,8:413.
[7]徐梓宁,黄敬君,周娟,等.程序性死亡受体-1单抗在肝动脉化疗栓塞联合分子靶向药物治疗后进展期肝细胞癌的疗效分析[J].中华内科杂志,2021,60:630-636.
[8]Zhu D,Ma K,Yang W,et al.Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma:a two-center propensity score matching study[J].Front Oncol,2022,12:1057560.
[9]Xia WL,Zhao XH,Guo Y,et al.Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma:a multicenter retrospective study[J].Front Oncol,2022,12:961394.
[10]Galle PR,Finn RS,Qin SK,et al.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma(IMbrave150):an open-label,randomised,phase 3 trial[J].Lancet Oncol,2021,22:991-1001.
[11]Tan Z,Zhang J.Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus[J].Eur Rev Med Pharmacol Sci,2023,27:8119-8134.
[12]Kim GA,Shim JH,Yoon SM,et al.Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis:a propensity score analysis[J].J Vasc Interv Radiol,2015,26:320-9.e6.
[13]Kudo M,Ueshima K,Ikeda M,et al.Randomised,multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J].Gut,2020,69:1492-1501.
[14]Patidar Y,Chandel K,Condati NK,et al.Transarterial chemoembolization(TACE)combined with sorafenib versus TACE in patients with BCLC stage C hepatocellular carcinoma:a retrospective study[J].J Clin Exp Hepatol,2022,12:745-754.
[15]Chen R,Li Y,Song K,et al.Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus:a retrospective study[J].J Gastrointest Oncol,2022,13:780-786.
[16]Sun T,Chen L,Kan X,et al.A comparative analysis of efficacy of apatinib combined with transarterial chemoembolization and transarterial chemoembolization alone in the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J].J Oncol,2022,2022:1255133.
[17]Cao Y,Sun T,Guo X,et al.Sorafenib versus apatinib both combined transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis:a comparative retrospective study[J].Front Oncol,2021,11:673378.
[18]Finn R,Qin S,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382:1894-1905.
[19]Finn R,Ikeda M,Zhu A,et al.Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J].J Clin Oncol,2020,38:2960-2970.
[20]Xu J,Shen J,Gu S,et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma(RESCUE):a nonrandomized,open-label,phase Ⅱ trial[J].Clin Cancer Res,2021,27:1003-1011.
[21]Jin ZC,Zhong BY,Chen JJ,et al.Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC(CHANCE2211):a propensity score matching study[J].Eur Radiol,2023,33:8669-8681.
[22]Zhang JX,Hua HJ,Cheng Y,et al.Role of transarterial chemoembolization in the era of tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy for unresectable hepatocellular carcinoma:a retrospective propensity score matched analysis[J].Acad Radiol,2024,31:1304-1311.
[23]Montasser A,Beaufrere A,Cauchy F,et al.Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma[J].Histopathology,2021,79:36-46.
[24]Cheu JW,Wong CC.Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors[J].Hepatology,2021,74:2264-2276.
[25]Sun T,Ren Y,Sun B,et al.The feasibility of TACE combined with TKIs plus PD-1 antibody for advanced HCC[J].J Hepatocell Carcinoma,2023,10:447-457.
[26]Xia WL,Zhao XH,Guo Y,et al.Transarterial chemoembolization combined with apatinib plus PD-1 inhibitors for hepatocellular carcinoma with portal vein tumor thrombus:a multicenter retrospective study[J].Clin Transl Gastroenterol,2023,14:e00581.
[27]Liu H,Yu Q,Gu T,et al.Transarterial chemoembolization plus apatinib with or without camrelizumab for the treatment of advanced HBV-related hepatocellular carcinoma[J].J Gastrointestin Liver Dis,2023,32:182-189.
[28]张学贤,丁雨寒,李 威,等.经导管动脉化疗栓塞联合仑伐替尼及卡瑞丽珠单抗治疗中晚期肝细胞癌临床效果[J].介入放射学杂志,2024,32:57-62.
[29]赵 莹,黎可人,杨艳美,等.放射治疗联合免疫检查点抑制剂及仑伐替尼治疗肝细胞癌合并门静脉癌栓的疗效分析[J].肝癌电子杂志,2023,10:58-63.
[30]Duan X,Li H,Kuang D,et al.Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma:a multicenter retrospective cohort study[J].Hepatol Int,2023,17:915-926.
[31]Gu X,Zhang S,Yang X,et al.Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma[J].BMC Gastroenterol,2022,22:441.
(收稿日期:2024-06-23)
(本文编辑:新 宇)
相似文献/References:
[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(07):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(07):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(07):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(07):535.
[5]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(07):442.
[6]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[7]吴纪瑞,杨永岩,杨熙章,等.丝裂霉素C微囊肝动脉化疗栓塞术治疗中晚期肝癌[J].介入放射学杂志,1992,(01):41.
[8]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[9]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(07):185.
[10]黄渊全,贾中芝,冯耀良,等.CT灌注成像在肝癌TACE术后疗效评价中的应用价值[J].介入放射学杂志,2009,(06):437.
HUANG Yuan-quan,JIA Zhong-zhi,FENG Yao-liang,et al.Clinical application of CT perfusion imaging in estimating the efficacy of transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J].J Intervent Med,2009,(07):437.
[11]曹志超,陈焕玉,张 宏,等.增强CT、多参数能谱CT及增强MR在肝癌TACE后评估的价值分析[J].介入放射学杂志,2025,34(09):971.[doi:10.3969/j.issn.1008-794X.2025.09.011]
CAO Zhichao,CHEN Huanyu,ZHANG Hong,et al.Application of enhanced CT,energy spectrum CT and enhanced MR in evaluating hepatocellular carcinoma after TACE treatment[J].J Intervent Med,2025,34(07):971.[doi:10.3969/j.issn.1008-794X.2025.09.011]